We are live on ! Find out more
RM

RP Management Portfolio holdings

AUM $139M
1-Year Est. Return 37.98%
This Fund
S&P 500
This Quarter Est. Return
+55.53%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$84.9M
AUM Growth
-$132M
Cap. Flow
-$127M
Cap. Flow %
-148.97%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$41.5M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$168M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
1
BioCryst Pharmaceuticals
BCRX
$2.52B
$44.2M 52%
3,846,154
– –
BHVN icon
2
Biohaven
BHVN
$2.43B
$40.8M 48%
+2,936,507
New +$41.5M
VIRX
3
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.4K 0.01%
3,700
– –
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-1,111,111
Closed -$168M

Similar funds

PC
Paradoxiom Capital Stamford, Connecticut $154M AUM
LA
LPF Advisors Sarasota, Florida $122M AUM 3.12% 1-Year Est. Return
TP
Thunderbird Partners London, United Kingdom $113M AUM 8.51% 1-Year Est. Return
SC
Serenity Capital Palo Alto, California $167M AUM
MADFP
Michael A Dubis Financial Planning Middleton, Wisconsin $103M AUM
RM
RCF Management Denver, Colorado $103M AUM
NC
Napatree Capital Westerly, Rhode Island $178M AUM 8.09% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

RP Management's Q4 2022 Portfolio in Review

As of Q4 2022, RP Management held 4 positions worth $84.9M, down 61% from $216M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

RP Management withdrew a net $127M in Q4 2022, closing 1 position. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $168M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, RP Management opened a new position in Biohaven worth $40.8M.

  • RP Management's largest Q4 2022 buy was Biohaven: 2,936,507 shares worth $40.8M.
  • RP Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $168M.
  • RP Management's ten largest holdings make up 100% of its $84.9M portfolio in Q4 2022.
  • RP Management opened 1 new position and closed 1 in Q4 2022.
  • RP Management's portfolio value fell 61% quarter-over-quarter to $84.9M.

Based on RP Management's 13F filing for Q4 2022, filed 14 Feb 2023.